{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:11:18Z","timestamp":1788930678898,"version":"build-2803163510"},"reference-count":119,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-\u03b2 (A\u03b2) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role for A\u03b2. Anti-A\u03b2 monoclonal antibodies substantially reduce amyloid burden and modestly slow clinical decline in early symptomatic AD. Continued decline despite plaque removal is consistent with ongoing downstream tau pathology, glial responses, and neuronal injury. This narrative review examines AD mechanisms, biomarkers, and therapeutic prospects from a geroscience perspective and applies the eight hallmarks of neurodegenerative diseases as an analytical framework. Advances in blood-based biomarkers, particularly plasma phosphorylated tau 217, may improve biological detection, but their clinical value depends on assay performance, intended use, and patient context. Gut dysbiosis and gut\u2013brain communication are considered separately as candidate systemic modifiers because causal evidence in humans remains insufficient. The hallmarks are overlapping analytical categories, not independent primary causes, and their therapeutic relevance depends on disease stage and pathway activity. Future studies should establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinically meaningful outcomes and identify the patients most likely to benefit.<\/jats:p>","DOI":"10.3390\/cells15171599","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:35:29Z","timestamp":1788359729000},"page":"1599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alzheimer\u2019s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6995-123X","authenticated-orcid":false,"given":"Piotr Pawe\u0142","family":"Chmielewski","sequence":"first","affiliation":[{"name":"Division of Anatomy, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 6a Chalubinskiego St., 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s Disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia Prevention, Intervention, and Care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"ref_5","unstructured":"GBD 2019 Dementia Forecasting Collaborators (2022). Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019. Lancet Public Health, 7, e105\u2013e125."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer Dement."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and Biomarker Changes in Dominantly Inherited Alzheimer\u2019s Disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The Cellular Phase of Alzheimer\u2019s Disease","volume":"164","author":"Karran","year":"2016","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of Neurodegenerative Diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.410270502","article-title":"Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: Correlation with cognitive severity","volume":"27","author":"DeKosky","year":"1990","journal-title":"Ann. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuron.2004.09.010","article-title":"Deciphering the Molecular Basis of Memory Failure in Alzheimer\u2019s Disease","volume":"44","author":"Walsh","year":"2004","journal-title":"Neuron"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer\u2019s Disease Is a Synaptic Failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s Disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: An expanding universe","volume":"186","author":"Blasco","year":"2023","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70535","DOI":"10.1002\/alz.70535","article-title":"Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Schindler","year":"2024","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s Disease: The Amyloid Cascade Hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The Amyloid Hypothesis of Alzheimer\u2019s Disease: Progress and Problems on the Road to Therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","article-title":"Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 Variants in Alzheimer\u2019s Disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer\u2019s disease","volume":"43","author":"Naj","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias","volume":"54","author":"Bellenguez","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1002\/alz.13873","article-title":"Assessing the lack of diversity in genetics research across neurodegenerative diseases: A systematic review of the GWAS Catalog and literature","volume":"20","author":"Jonson","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00401-011-0825-z","article-title":"Alzheimer\u2019s pathogenesis: Is there neuron-to-neuron propagation?","volume":"121","author":"Braak","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Clifford","year":"2016","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The Diagnosis of Dementia Due to Alzheimer\u2019s Disease: Recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association Workgroups on Diagnostic Guidelines for Alzheimer\u2019s Disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: Recent highlights from the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"15","author":"Veitch","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"In Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer\u2019s Association on \u201cThe Preclinical State of AD\u201d, Washington DC, USA, 23 July 2015; Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"a011452","DOI":"10.1101\/cshperspect.a011452","article-title":"Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease","volume":"2","author":"Sagare","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of Factors with Elevated Amyloid Burden in Clinically Normal Older Individuals","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward Defining the Preclinical Stages of Alzheimer\u2019s Disease: Recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association Workgroups on Diagnostic Guidelines for Alzheimer\u2019s Disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.15252\/emmm.201707809","article-title":"18F-AV-1451 and CSF T-tau and P-tau as Biomarkers in Alzheimer\u2019s Disease","volume":"9","author":"Mattsson","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2047-9158-3-6","article-title":"In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals","volume":"3","author":"Zimmer","year":"2014","journal-title":"Transl. Neurodegener."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Normandin","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET","volume":"12","author":"Visani","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A Unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease","volume":"169","author":"Spinrad","year":"2017","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","article-title":"The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases","volume":"47","author":"Krasemann","year":"2017","journal-title":"Immunity"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuron.2016.05.003","article-title":"TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy","volume":"90","author":"Yuan","year":"2016","journal-title":"Neuron"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e20200785","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","article-title":"Immune attack: The role of inflammation in Alzheimer disease","volume":"16","author":"Heppner","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-024-00402-3","article-title":"Emerging role of senescent microglia in brain aging-related neurodegenerative diseases","volume":"13","author":"Rim","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular Senescence: Defining a Path Forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuron.2017.07.030","article-title":"The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease","volume":"96","author":"Iadecola","year":"2017","journal-title":"Neuron"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/CIRCRESAHA.118.313260","article-title":"Neurovascular and Cognitive Dysfunction in Hypertension","volume":"124","author":"Iadecola","year":"2019","journal-title":"Circ. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/archneurol.2009.27","article-title":"The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged","volume":"66","author":"Craft","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2005-7106","article-title":"Review of Insulin and Insulin-Like Growth Factor Expression, Signaling, and Malfunction in the Central Nervous System: Relevance to Alzheimer\u2019s Disease","volume":"7","author":"Wands","year":"2005","journal-title":"J. Alzheimers Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuron.2017.01.022","article-title":"Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities","volume":"93","author":"Menzies","year":"2017","journal-title":"Neuron"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/ejn.12169","article-title":"Autophagy failure in Alzheimer\u2019s disease and the role of defective lysosomal acidification","volume":"37","author":"Wolfe","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.bbadis.2013.10.015","article-title":"Oxidative Stress and Mitochondrial Dysfunction in Alzheimer\u2019s Disease","volume":"1842","author":"Wang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and Mitochondrial Cascades in Alzheimer\u2019s Disease","volume":"62","author":"Swerdlow","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ncl.2023.01.001","article-title":"Sex Differences in Alzheimer\u2019s Disease","volume":"41","author":"Aggarwal","year":"2023","journal-title":"Neurol. Clin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women\u2019s Health Initiative Memory Study: A Randomized Controlled Trial","volume":"289","author":"Shumaker","year":"2003","journal-title":"JAMA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2967\/jnumed.120.245209","article-title":"Determining Amyloid-\u03b2 Positivity Using 18F-AZD4694 PET Imaging","volume":"62","author":"Therriault","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","article-title":"Alzheimer disease blood biomarkers: Considerations for population-level use","volume":"20","author":"Mielke","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3233\/JAD-230067","article-title":"Creating an Unprotected Class: Addressing Legal Risks in the Era of Biologically-Defined Alzheimer\u2019s Disease","volume":"98","author":"Vaishnav","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease","volume":"143","author":"Janelidze","year":"2020","journal-title":"Brain"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1111\/jgs.18426","article-title":"Passive digital markers for Alzheimer\u2019s disease and other related dementias: A systematic evidence review","volume":"71","author":"Taylor","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated Brain Volume Loss Caused by Anti-\u03b2-Amyloid Drugs: A Systematic Review and Meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A Phase 3 Trial of Semagacestat for Treatment of Alzheimer\u2019s Disease","volume":"369","author":"Doody","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer\u2019s Disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Aisen","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: Current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_97","first-page":"e70251","article-title":"Alzheimer\u2019s Disease Drug Development Pipeline: 2026","volume":"12","author":"Cummings","year":"2026","journal-title":"Alzheimers Dement."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","article-title":"Senolytic therapy in mild Alzheimer\u2019s disease: A phase 1 feasibility trial","volume":"29","author":"Gonzales","year":"2023","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.STR.0000014421.15948.67","article-title":"Alzheimer Disease as a Vascular Disorder: Nosological Evidence","volume":"33","year":"2002","journal-title":"Stroke"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the Right Target and Right Drug at the Right Stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: Adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/jnnp.49.3.229","article-title":"Alzheimer\u2019s Disease: A Correlative Study","volume":"49","author":"Neary","year":"1986","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease","volume":"41","author":"Hollister","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_105","first-page":"31","article-title":"A\u03b2 Plaques","volume":"1","author":"Walker","year":"2020","journal-title":"Free Neuropathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/bs.pbr.2020.07.016","article-title":"Alterations and Interactions of Subcortical Modulatory Systems in Alzheimer\u2019s Disease","volume":"261","author":"Hof","year":"2021","journal-title":"Prog. Brain Res."},{"key":"ref_107","first-page":"e70098","article-title":"Alzheimer\u2019s Disease Drug Development Pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The Microbiota-Gut-Brain Axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2016.08.019","article-title":"Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly","volume":"49","author":"Cattaneo","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3233\/JAD-200306","article-title":"Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer\u2019s Disease","volume":"78","author":"Marizzoni","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","article-title":"Altered bile acid profile associates with cognitive impairment in Alzheimer\u2019s disease\u2014An emerging role for gut microbiome","volume":"15","author":"MahmoudianDehkordi","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"13537","DOI":"10.1038\/s41598-017-13601-y","article-title":"Gut microbiome alterations in Alzheimer\u2019s disease","volume":"7","author":"Vogt","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Jemimah, S., Chabib, C.M.M., Hadjileontiadis, L., and AlShehhi, A. (2023). Gut microbiome dysbiosis in Alzheimer\u2019s disease and mild cognitive impairment: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285346"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2271613","DOI":"10.1080\/19490976.2023.2271613","article-title":"Gut microbiome-targeted therapies for Alzheimer\u2019s disease","volume":"15","author":"Zhang","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41591-021-01552-x","article-title":"Reporting guidelines for human microbiome research: The STORMS checklist","volume":"27","author":"Mirzayi","year":"2021","journal-title":"Nat. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1093\/brain\/awad303","article-title":"Microbiota from Alzheimer\u2019s patients induce deficits in cognition and hippocampal neurogenesis","volume":"146","author":"Grabrucker","year":"2023","journal-title":"Brain"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e20200895","DOI":"10.1084\/jem.20200895","article-title":"Gut microbiota\u2013driven brain A\u03b2 amyloidosis in mice requires microglia","volume":"219","author":"Dodiya","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O.R., Hamidi, G.A., and Salami, M. (2016). Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer\u2019s disease: A randomized, double-blind and controlled trial. Front. Aging Neurosci., 8.","DOI":"10.3389\/fnagi.2016.00256"},{"key":"ref_119","first-page":"160","article-title":"Probiotics for dementia: A systematic review and meta-analysis of randomized controlled trials","volume":"79","author":"Hillesheim","year":"2020","journal-title":"Nutr. Rev."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:45:57Z","timestamp":1788929157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":119,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15171599"],"URL":"https:\/\/doi.org\/10.3390\/cells15171599","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}